There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hookipa Pharma (HOOK – Research Report) ...

Thank you for standing by. Welcome to the Merck & Co. Q3 sales and earnings conference call. (Operator Instructions) This call is being recorded. If you have any objections, you may disconnect at this ...

Pfizer Inc Louise Chen; Analyst; Cantor Fitzgerald & Co. Inc. Geoff Meacham; Analyst; Citigroup Inc. (Operator Instructions) Good day, everyone, and welcome to Pfizer's third-quarter 2024 earnings ...

Mikael Dolsten; Chief Scientific Officer & President, Pfizer Research and Development; Pfizer Inc Andrew Baum; Chief Strategy and Innovation Officer & Executive Vice President; Pfizer Inc Louise Chen; ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

The company had reported a loss of 56 cents per share in the year-ago quarter. Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885.

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

Everyone knows that big pharma companies like Eli Lilly (NYSE: LLY) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren't ...